<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0005">
 <label>Table 1</label>
 <caption>
  <p>COVID-19 Vaccine Candidates in Clinical Development (21 as of June 29, 2020).</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Vaccine Candidate</th>
    <th>Platform</th>
    <th>Phase of Clinical Development</th>
    <th>Developer</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>ChAdOx1-S expressing S protein</td>
    <td>Non Replicating Viral Vector</td>
    <td>Phase 3</td>
    <td>University of Oxford, AstraZeneca</td>
   </tr>
   <tr>
    <td>Adenovirus Type 5 Vector expressing S protein</td>
    <td>Non Replicating Viral Vector</td>
    <td>Phase 2</td>
    <td>CanSino Biological Inc., Beijing Institute of Biotechnology</td>
   </tr>
   <tr>
    <td>Lipid nanoparticle (LNP) encapsulated mRNA encoding S protein</td>
    <td>RNA</td>
    <td>Phase 2</td>
    <td>Moderna, NIAID</td>
   </tr>
   <tr>
    <td>Inactivated</td>
    <td>Inactivated</td>
    <td>Phase 1/2</td>
    <td>Beijing Institute of Biological Products, Sinopharm</td>
   </tr>
   <tr>
    <td>Inactivated</td>
    <td>Inactivated</td>
    <td>Phase 1/2</td>
    <td>Wuhan Institute of Biological Products, Sinopharm</td>
   </tr>
   <tr>
    <td>Inactivated with alum</td>
    <td>Inactivated</td>
    <td>Phase 1/2</td>
    <td>Sinovac</td>
   </tr>
   <tr>
    <td>Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M</td>
    <td>Protein Subunit</td>
    <td>Phase 1/2</td>
    <td>Novavax</td>
   </tr>
   <tr>
    <td>3 LNP-mRNAs</td>
    <td>RNA</td>
    <td>Phase 1/2</td>
    <td>BioNTech, Fosun Pharma, Pfizer</td>
   </tr>
   <tr>
    <td>Inactivated</td>
    <td>Inactivated</td>
    <td>Phase 1/2</td>
    <td>Institute of Medical Biology, Chinese Academy of Medical Sciences</td>
   </tr>
   <tr>
    <td>Adeno-based</td>
    <td>Non Replicating Viral Vector</td>
    <td>Phase 1</td>
    <td>Gamaleya Research Institute</td>
   </tr>
   <tr>
    <td>DNA plasmid encoding S protein delivered by electroporation</td>
    <td>DNA</td>
    <td>Phase 1</td>
    <td>Inovio Pharmaceuticals</td>
   </tr>
   <tr>
    <td>DNA Vaccine (GX-19)</td>
    <td>DNA</td>
    <td>Phase 1</td>
    <td>Genexine Consortium</td>
   </tr>
   <tr>
    <td>LNP-nCoVsaRNA</td>
    <td>Self-amplifying RNA</td>
    <td>Phase 1</td>
    <td>Imperial College London</td>
   </tr>
   <tr>
    <td>mRNA</td>
    <td>RNA</td>
    <td>Phase 1</td>
    <td>Curevac</td>
   </tr>
   <tr>
    <td>mRNA</td>
    <td>RNA</td>
    <td>Phase 1</td>
    <td>People's Liberation Army (PLA) Academy of Military Sciences, Walvax Biotech</td>
   </tr>
   <tr>
    <td>S-Trimer subunit vaccine adjuvanted</td>
    <td>Protein Subunit</td>
    <td>Phase 1</td>
    <td>Clover Biopharmaceuticals, GSK, Dynavax</td>
   </tr>
   <tr>
    <td>Adjuvanted recombinant protein (RBD Dimer)</td>
    <td>Protein Subunit</td>
    <td>Phase 1</td>
    <td>Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology, Chinese Academy of Sciences</td>
   </tr>
   <tr>
    <td>Autologous Dendritic Cells with SARS-CoV-2 antigens, administered with granulocyteâ€“macrophage colony-stimulating factor (GM-CSF)</td>
    <td>Dendritic cell vaccine</td>
    <td>Phase 1</td>
    <td>Aivita Biomedical</td>
   </tr>
   <tr>
    <td>Dendritic cells (DC) modified with lentivirus vector, expressing synthetic minigene based on domains of selected viral proteins, administered with antigen specific cytotoxic T lymphocytes (CTLs)</td>
    <td>Modified DC</td>
    <td>Phase 1</td>
    <td>Shenzhen Geno-Immune Medical Institute</td>
   </tr>
   <tr>
    <td>Artificial antigen-presenting cells (aAPCs) modified with lentiviral vector, expressing synthetic minigene based on domains of selected proteins</td>
    <td>Modified APCs</td>
    <td>Phase 1</td>
    <td>Shenzhen Geno-Immune Medical Institute</td>
   </tr>
   <tr>
    <td>bac-TRL Spike, orally delivered</td>
    <td>Live Bifidobacterium longum to deliver plasmids of synthetic DNA encoding SARS-CoV-2 spike protein</td>
    <td>Phase 1</td>
    <td>Symvivo</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Source- ClinicalTrials.gov, London School of Hygiene and Tropical Medicine 
    <xref rid="b0020" ref-type="bibr">[4]</xref>, WHO 
    <xref rid="b0025" ref-type="bibr">[5]</xref>.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
